Special Issue "Biologics"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 January 2013)
Dr. Christine Brezden-Masley
St. Michael’s Hospital, 30 Bond Street, Room 2046, Toronto, Ontario, Canada
Interests: cytotoxic chemotherapeutics; molecular-targeted biologics; breast cancer pathophysiology; diagnostic imaging; patient safety
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- novel molecular targets of cancer pathogenesist
- tumour biomarkers
- novel tyrosine kinase inhibitors
- molecular targeted monoclonal antibodies
- targets of tumorigenesis
- pathways of inhibition of tumorigenesis
Pharmaceuticals 2012, 5(1), 79-93; doi:10.3390/ph5010079
Received: 16 November 2011; in revised form: 14 December 2011 / Accepted: 22 December 2011 / Published: 5 January 2012| Download PDF Full-text (699 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(4), 353-368; doi:10.3390/ph5040353
Received: 20 February 2012; in revised form: 20 March 2012 / Accepted: 28 March 2012 / Published: 30 March 2012| Download PDF Full-text (97 KB) | Download XML Full-text
Review: Inactivation of Caliciviruses
Pharmaceuticals 2013, 6(3), 358-392; doi:10.3390/ph6030358
Received: 28 January 2013; in revised form: 20 February 2013 / Accepted: 5 March 2013 / Published: 21 March 2013| Download PDF Full-text (577 KB) | Download XML Full-text
Article: Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection
Pharmaceuticals 2013, 6(3), 393-406; doi:10.3390/ph6030393
Received: 29 January 2013 / Accepted: 13 March 2013 / Published: 21 March 2013| Download PDF Full-text (697 KB) | Download XML Full-text
Review: Biologics in Dermatology
Pharmaceuticals 2013, 6(4), 557-578; doi:10.3390/ph6040557
Received: 31 January 2013; in revised form: 26 February 2013 / Accepted: 7 April 2013 / Published: 17 April 2013| Download PDF Full-text (485 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(5), 579-603; doi:10.3390/ph6050579
Received: 1 March 2013; in revised form: 28 March 2013 / Accepted: 10 April 2013 / Published: 26 April 2013| Download PDF Full-text (476 KB) | Download XML Full-text
Pharmaceuticals 2013, 6(5), 681-688; doi:10.3390/ph6050681
Received: 5 February 2013; in revised form: 23 April 2013 / Accepted: 8 May 2013 / Published: 14 May 2013| Download PDF Full-text (134 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Molecularly Based Approach to Malignant Pleural Mesothelioma Therapy: State of the Art.
Authors: Giulia M Stella, Simona Inghilleri, Maurizio Luisetti, Francesca Cemmi, Laura Saracino and Michele Zorzetto
Affiliation: Department of Hematological, Pneumological and Cardiovascular Sciences - Section of Pneumology, University and Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy; E-Mail: firstname.lastname@example.org
Abstract: Malignant Pleural Mesothelioma (MPM) is an ominous disease with a severe prognosis still lacking of effective therapeutic regimens. MPM is increasing as a consequence to the worldwide exposure to asbestos fibres. Little is known about the molecular biology which drives MPM onset. Somatic genetic lesions affecting the oncogenes known to have a causative role in epithelial cancers, are rarely found in MPM. This is most likely an implication of the histological origin of mesothelial cells as well as of asbestos mechanism of transformation. A better understanding of MPM biology and identification of MPM specific targettable markers is a clear priority of both scientist and clinicians. This reviewed is aimed to evaluate the state of the art MPM most recent molecular findings, which will lead to successful tailored therapeutic options.
Type of Paper: Review
Title: Trends in Biologics Manufacturing in India
Author: Karen Politis Virk
Affiliation: Director of Biotech & Pharmaceutical Research, Language Connections - A Language Service Provider; E-Mail: email@example.com
Abstract: Due to the high cost of drug development, there has been a growing interest in offshoring manufacturing to emerging countries where the cost is significantly less. However, this has been somewhat hindered by the limited ability of companies to ensure biologic equivalence in the molecules produced at offshoring sites. In addition, inconsistent compliance with established regulatory procedures, inadequate IP protection, differences in regulatory approval requirements for biologics and linguistic and cultural barriers all create significant hurdles. Despite the challenges, many companies are increasingly considering transferring manufacturing to emerging countries, particularly those with experience in drug manufacturing. As a result, India is emerging as one of the most dominant offshoring locations. Among the reasons for this is the country's well-established generics manufacturing sector and the high rate of English proficiency among Indian scientists. In addition to improved oversight and regulatory reforms, however, India's regional linguistic and cultural diversity must be addressed. As Western pharmaceutical companies increasingly choose to collaborate with Indian companies in an effort to produce more affordable biogenerics, they are discovering the importance of addressing communication barriers.
Last update: 7 September 2012